NEW HOPE, Pa.--(BUSINESS WIRE)--Nov. 11, 2005--Protalex, Inc. (OTCBB:PRTX) today announced the appointment of Peter G. Tombros to the Company’s board of directors. From 2001-2005 Mr. Tombros served as chief executive officer and chairman of Vivoquest, a private biotechnology company until its sale to XTL in September 2005. Mr. Tombros served as president and chief executive officer of Enzon from 1994 to 2001 and oversaw its transition from significant losses to profitability. During that time, Enzon’s market cap grew from $44 million to $3 billion, and Enzon enjoyed a position as one of the top biotech firms in the world. Prior to Enzon, Mr. Tombros spent 25 years with Pfizer where he helped build the pharmaceutical business as executive vice president of Pfizer Pharmaceuticals, Inc. Mr. Tombros also served as vice president corporate strategic planning where he was responsible for mergers and acquisitions and oversight of the Pfizer Venture Capital investments. Mr. Tombros is also a director of several public companies. Mr. Tombros received B.S. and M.S. degrees from the Pennsylvania State University and an M.B.A. from the University of Pennsylvania, Wharton Graduate School of Business. He was recently appointed professor in the Eberly College of Science BS/MBA program, an accelerated honors program designed to train scientists to become business leaders.
